A global open-label, prospective, multi-center, randomized, Phase II trial with two treatment arms designed to assess the safety and efficacy of TheraSphere administered before initiation of Durvalumab with Tremelimumab in HCC patients not eligible for or who have declined treatment with resection and/or ablation or liver transplant.
The objective of the ROWAN clinical study is to assess the durability of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone.